Home
/ Alnylam
/ Competitors

Alnylam Competitors and Similar CompaniesClear all

Alnylam's competitors and similar companies include Celyad, Sorrento Therapeutics, Regulus Therapeutics and Ionis Pharmaceuticals.

	Alnylam Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments.	Celyad Celyad is a biopharmaceutical company focused on the discovery and development of regenerative and protective therapies in cardiology and oncology.	Sorrento Therapeutics Sorrento Therapeutics is focused on the development of proprietary drug therapeutics for addressing unmet medical needs.	Regulus Therapeutics Regulus Therapeutics is a biopharmaceutical company involved in the R&D of high-impact medicines based on microRNAs.	Ionis Pharmaceuticals Ionis Pharmaceuticals (formerly known as Isis Pharmaceuticals) is a company that discovers and develops RNA-targeted therapeutics.
Founding Date	Founding Date 2002	Founding Date 2007	Founding Date 2006	Founding Date 2007	Founding Date 1989
Type	Type Public	Type Public	Type Public	Type Public	Type Public
Tags	Tags Healthcare biotech pharma	Tags Healthcare biotech healthtech pharma	Tags Healthcare biotech healthtech pharma	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development genetics pharma
Locations	Locations Cambridge, US HQ Paris, FR Milan, IT Tokyo, JP Amsterdam, NL Stockholm, SE Zug, CH see more	Locations Mont-Saint-Guibert, BE HQ New York, US	Locations San Diego, US HQ San Diego, US	Locations San Diego, US HQ	Locations Carlsbad, US HQ
Employees	Employees 1,32324% increase	Employees 17	Employees 31019% decrease	Employees 2462% decrease	Employees 92716% increase
Valuation ($)	Valuation ($) 36.5 b	Valuation ($) 11.8 m	Valuation ($) 1.5 m	Valuation ($) 105.4 m	Valuation ($) 6.3 b
Financial
Revenue (est.)	Revenue (est.) $1.8b (FY, 2023)	Revenue (est.) €102k (FY, 2023)	Revenue (est.) $62.8m (FY, 2022)	Revenue (est.) N/A	Revenue (est.) $787.6m (FY, 2023)
Cost of goods	Cost of goods $268.2m (FY, 2023)	Cost of goods €69k (FY, 2023)	Cost of goods N/A	Cost of goods N/A	Cost of goods $9.1m (FY, 2023)
Gross profit	Gross profit $1.6b (FY, 2023)	Gross profit €1.4m (FY, 2023)	Gross profit N/A	Gross profit N/A	Gross profit $778.5m (FY, 2023)
Net income	Net income ($440.2m) (FY, 2023)	Net income (€8.4m) (FY, 2023)	Net income ($577.8m) (FY, 2022)	Net income ($30m) (FY, 2023)	Net income ($366.3m) (FY, 2023)
Funding
Total funding raised	Total funding raised $ 1.5b	Total funding raised N/A	Total funding raised $ 42.6m	Total funding raised $ 10m	Total funding raised N/A